Clinical Trials Directory

Trials / Unknown

UnknownNCT01236820

A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients

L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients

Status
Unknown
Phase
Study type
Observational
Enrollment
48 (estimated)
Sponsor
China Medical University Hospital · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether L5, one of the Low Density Lipoproteins, is an effective predicting factor for cardiovascular disease in chronic renal and hemodialytic patients.

Detailed description

Cardiovascular disease (CVD) is the most important cause of death of chronic kidney disease (CKD) and hemodialysis (HD) patients. Low Density Lipoprotein (LDL) is an essential indicator of CVD.The higher the plasma LDL level, the higher the risk of CVD. LDL is a heterogenous substance composed of different mass and size. Oxidized LDL (oxLDL) is the oxidation product of LDL and is the most important component of LDL associated with CVD. The oxLDL is mostly trapped within tissue and not easily to be detected from blood. L5 iw a kind of electronegative LDL and is associated with CVD in smokers and diabetic patients, even if these patients have normal plasma LDL. Uremia patients have lipid profile different from that of general people,while HD Patients have lower LDL and CKD patients have LDL higher than that of general population. Thus LDL plasma level cannot fully explain the high risk of CVD in CKD and HD patients. As patients with normal LDL but high L5 are prone to have CVD, we suspect there might be association of L5 with CVD in both CKD and HD patients.

Conditions

Timeline

Start date
2010-09-01
First posted
2010-11-09
Last updated
2010-11-09

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT01236820. Inclusion in this directory is not an endorsement.